Metsera, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Christopher Whitten Bernard
- Full Time Employees
- 93
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 3 World Trade Center New York City NY United States of America 10007
- IPO Date
- Jan 31, 2025
- CIK
- 0002040807
- Website
- metsera.com
- Similar Companies
- Business
- Metsera, Inc. (NasdaqGS: MTSR) is a clinical-stage biotechnology company focused on developing innovative therapies for obesity and metabolic diseases. The company offers a pipeline of proprietary peptide-based therapies targeting GLP-1 and GIP receptors; these include its lead candidate, MET-097i, an optimized long-acting amylin analog designed for once-weekly dosing, as well as earlier-stage assets like dual amylin-GLP-1 agonists and oral formulations for weight management. Metsera provides research and development services in peptide engineering, formulation technologies, and clinical trial execution for metabolic disorders, serving patients and healthcare providers in the endocrinology sector. Founded in 2023 and headquartered in South San Francisco, California, Metsera operates primarily in the United States with clinical trials conducted globally across North America, Europe, and Asia. The company targets the expanding obesity treatment market, estimated at over 1 billion adults worldwide, with therapies aimed at superior efficacy, tolerability, and convenience compared to existing incretin mimetics. Subsidiaries include Metsera Therapeutics Ltd. in the UK for European operations, with no parent company. In the past year, Metsera completed its initial public offering in the second quarter of 2025, raising approximately $400 million to advance its pipeline into Phase 2 trials; announced positive topline data from Phase 1b/2a trials of MET-097i in October 2025, demonstrating up to 15% weight loss at 12 weeks with favorable safety; and formed a strategic research collaboration with a leading peptide chemistry firm to accelerate next-generation oral candidates. The company expanded its manufacturing partnerships in Q3 2025 to support scale-up for late-stage development and initiated enrollment in a global Phase 2 obesity study across multiple sites. These developments position Metsera for accelerated growth in the competitive GLP-1 agonist landscape.
IP Group shares jump 9% as Metsera deal drives return to growth
Metsera Inc. (NASDAQ:MTSR) Given Average Recommendation of “Hold” by Brokerages
Pfizer Completes Acquisition of Metsera
Metsera shareholders vote for $10 billion acquisition by Pfizer
Why Metsera's Share Price Is Plummeting This Week
Instacart Up on Earnings Beat; Metsera Down on Takeover Battle | Stock Movers
Pfizer to acquire Metsera after winning bidding contest against Novo Nordisk
Pfizer to buy Metsera in deal worth up to $10 billion
Pfizer CEO: Metsera deal gives us 'one of the most exciting, advanced portfolios' in obesity drugs
5 Things to Know Before the Stock Market Opens
Pfizer Is Buying Weight-Loss Drugmaker Metsera. Why Novo Nordisk Is the Winner.
Monday.Com, Metsera, Profrac Holding And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Novo Nordisk Shares Rise After Withdrawal from Metsera Takeover Battle
Novo Nordisk shares rise after dropping Metsera bid
Wall Street Brunch: Here Come The 13Fs
Novo Nordisk will not increase its proposal to acquire Metsera, Inc.
Pfizer has agreed to buy weight-loss drug startup Metsera in a deal that could be worth more than $10 billion, besting rival Novo Nordisk following a heated bidding war
Pfizer and Metsera Enter into Merger Agreement Amendment; Metsera's Board of Directors Reaffirms Support of Merger with Pfizer
Pfizer sweetens offer for Metsera in bidding war against Novo, Bloomberg News reports
Novo CEO says its bid for Metsera is higher